Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies
- 30 June 2023
- journal article
- research article
- Published by Elsevier in Brachytherapy
- Vol. 22 (5) , 630-639
Abstract
No abstract availableKeywords
Funding Information
- National Center for Research Resources
- National Center for Advancing Translational Sciences
- National Institutes of Health (5UL1TR001436-02)
This publication has 25 references indexed in Scilit:
- The epidemiology of venous thromboembolismJournal of Thrombosis and Thrombolysis, 2016
- Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical PatientsJAMA Surgery, 2015
- Is venous thromboprophylaxis necessary in patients undergoing minimally invasive surgery for a gynecologic malignancy?Gynecologic Oncology, 2014
- Validation of a venous thromboembolism risk assessment model in gynecologic oncologyGynecologic Oncology, 2014
- Prevention of VTE in Nonorthopedic Surgical PatientsChest, 2012
- American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principlesBrachytherapy, 2012
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Venous thromboembolism in cervical cancerThe Lancet Oncology, 2008
- Thrombosis Risk Assessment as a Guide to Quality Patient CareDisease-a-Month, 2005
- Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for CancerNew England Journal of Medicine, 2002